About Apremilast (Form B) API
Categoría Terapéutica Anti-Inflammatory
Número CAS
608141-41-9
Tecnología del API
Sintética
Forma de Dosificación
Tabletas
Estado de Desarrollo en Dr. Reddy’s
Disponible
Presentación Regulatoria Disponible
DMF de Corea, DMF de China, USDMF
Mechanism of Action
Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.
Indication
OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
- Adult patients with active psoriatic arthritis
- Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Apremilast (Form B)
Anti-Inflammatory
